替尔泊肽治疗2型糖尿病的快速卫生技术评估

打开文本图片集

【中图分类号】 R977.1+5 【文献标识码】A

【Abstract】Objective To conduct a rapid health technology assessment （rHTA） of the efficacy，safety，and cost-effectiveness of tirzepatide for the treatment of type 2 diabetes mellitus （T2DM），and to provide evidence for clinical medication. Methods PubMed，Web of Science， Embase， Cochrane Library，WanFang Data， CNKI databases，and health technology assessment （HTA）websites were searched to collect systematic reviews/Meta-analysis， pharmacoecomic literature and HTA reports of tirzepatide in the treatment of T2DM from inception to February 28， 2025.Two researchers independently conducted literature screening， data extraction，and quality assessment， and then summarized and analyzed the results. Results A total of 13 articles were included，comprising 2HTA reports，8 systematic reviews/Meta-analyses，and 3 pharmacoeconomic studies. In terms of effcacy，tirzepatide outperformed placebo or other antidiabetic drugs in reducing glycated hemoglobin （HbAlc）， increasing the rate of HbAlc <7% ，lowering blood glucose， and reducing weight. The antihyperglycemic and weight-loss effctsof tirzepatide were dose-dependent，and it alsohad certain advantages in reducing the risk of cardiovascular events and renal composite endpoint events.Regarding safety， the incidence of gastrointestinal adverse events in the tirzepatide group was higher than that in the placebo group and the insulin group，mainly manifested as diarrhea， nausea，and vomiting.However， it did not increase the risk ofserious gastrointestinal adverse events，nor did it increase the risk of hypoglycemiaand pancreatitis.In terms of cost-effectiveness，tirzepatide had cost-utility and cost-efectivenessadvantages compared with semaglutide and other antidiabetic drugs. Conclusion Compared with other antidiabetic drugs， tirzepatide has better efficacy， safety， and cost-effectiveness in the treatment of T2DM.

【Keywords】Tirzepatide; Type 2 diabetes melitus; Rapid health technology assessment; Efficacy： Safety; Cost-effectiveness

全球糖尿病发病率显著上升，2023年流行病学研究[显示，中国有1.164亿糖尿病患者，主要为2型糖尿病（type2diabetesmellitus，T2DM）患者，多数伴有肥胖。（剩余15408字）